Sager Z

Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

7 papers · ORCID

ArticlePsilocybin

Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy.

Beaussant Y, Sager Z, Brennan C +14

Europe PMC2026
ArticlePsychedelics

Views on Psychedelic-Assisted Therapy for Substance Use Disorders from Individuals with Opioid Use Disorder and a History of Injection-Related Infections: A Qualitative Study.

Szpak V, Maddams S, Kim A +2

Europe PMC2026
ArticlePsilocybin

Set and setting in psilocybin-assisted therapy: A qualitative study of patients with cancer and depression.

Beaussant Y, Tarbi E, Nigam K +9

Europe PMC2025
ArticlePsychedelics

Survey of Massachusetts peer recovery coaches' attitudes toward the use of psychedelics to treat substance use disorders.

Szpak V, Kim A, Sager Z +1

Europe PMC2024
ArticlePsychedelics

Older Adults in Psychedelic-Assisted Therapy Trials: A Systematic Review

Bouchet L, Sager Z, Yrondi A +5

Europe PMC2024
ArticlePsilocybin

Older adults in psychedelic-assisted therapy trials: A systematic review.

Bouchet L, Sager Z, Yrondi A +5

Europe PMC2024
ArticlePsilocybin

Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.

Rosa WE, Sager Z, Miller M +19

Europe PMC2022